Hennion & Walsh Asset Management Inc. Grows Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 48.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,166 shares of the company's stock after buying an additional 14,426 shares during the period. Hennion & Walsh Asset Management Inc.'s holdings in Apellis Pharmaceuticals were worth $966,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of APLS. Entropy Technologies LP bought a new stake in Apellis Pharmaceuticals in the 4th quarter worth about $445,000. Savant Capital LLC increased its holdings in Apellis Pharmaceuticals by 42.5% in the 4th quarter. Savant Capital LLC now owns 31,525 shares of the company's stock worth $1,006,000 after buying an additional 9,407 shares in the last quarter. Banque Pictet & Cie SA increased its holdings in Apellis Pharmaceuticals by 31.7% in the 4th quarter. Banque Pictet & Cie SA now owns 97,299 shares of the company's stock worth $3,105,000 after buying an additional 23,416 shares in the last quarter. Ieq Capital LLC increased its holdings in Apellis Pharmaceuticals by 1,425.5% in the 4th quarter. Ieq Capital LLC now owns 126,710 shares of the company's stock worth $4,043,000 after buying an additional 118,404 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its holdings in Apellis Pharmaceuticals by 10.9% in the 4th quarter. Handelsbanken Fonder AB now owns 30,600 shares of the company's stock worth $976,000 after buying an additional 3,000 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Stock Up 0.9%

APLS stock opened at $19.28 on Friday. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $43.76. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The stock has a market cap of $2.42 billion, a P/E ratio of -9.50 and a beta of 0.73. The business's 50-day moving average price is $18.47 and its 200-day moving average price is $25.64.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $149.90 million for the quarter, compared to analysts' expectations of $197.61 million. During the same period in the previous year, the firm earned ($0.54) earnings per share. The firm's quarterly revenue was down 3.2% on a year-over-year basis. On average, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Wells Fargo & Company lifted their price objective on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an "equal weight" rating in a report on Monday, June 2nd. Wedbush dropped their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Mizuho dropped their target price on Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Finally, Royal Bank of Canada dropped their target price on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Nine analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $40.05.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.